About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...
But the rollout is now being wielded as a political tool. What that “America First” slogan actually means for global health ...
The United States has begun distributing a groundbreaking HIV-prevention treatment to two African nations, marking a ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.
The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.
The United States has delivered the first doses of Lenacapavir, a new long-acting HIV prevention drug, to Eswatini and Zambia ...
Tatenda Makoni is a Zimbabwean-born medical student at the Medical College of Wisconsin whose work bridges global health and ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback